A Phase 2b Dose-Ranging Randomized Double-Blind Placebo-Controlled Multicenter Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension
Brief description of study
The purpose of this research study is to understand the effects of rodatristat ethyl in subjects with PAH. It is expected that approximately 90 subjects with PAH will participate in this study at about 45-50 study sites in the US, Canada and Europe. The researchers who are conducting the study hope to understand the side effects of rodatristat ethyl in subjects with PAH as well as see if rodatristat ethyl may improve PAH symptoms. In addition, to better understand how the body processes rodatristat ethyl and how the rodatristat ethyl impacts serotonin levels in patients with PAH.
Clinical Study Identifier: s21-00106
ClinicalTrials.gov Identifier: NCT04712669
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
